By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



1055 E. Colorado Boulevard. Fifth Floor

Pasadena  California  91106  U.S.A.
Phone: 323-721-5500 Fax: 323-721-9131


Company News
Genervon Release: GM604 To Be Granted "Orphan Drug" Status In Europe 5/3/2016 9:24:27 AM
Genervon GM604 Reduced TDP-43 Protein Aggregates And Slowed Down ALS Progression 9/22/2015 10:48:04 AM
Genervon Filed Patent For Using GM604 Modulations Of ALS Disease Biomarkers Showing Homeostasis, Leading To Prognosis And Therapeutic Treatment For ALS Disease 6/29/2015 10:39:54 AM
FDA, Genervon and ALS Blogger Battle Over Clinical Trial Interpretation 4/21/2015 6:52:00 AM
Genervon Announces ALS Compassionate Use Results 1/8/2015 10:56:03 AM
Genervon Announces ALS And PD Phase 2a Trial Results 10/20/2014 9:29:21 AM
Genervon Announces Biomarker Data From GALS-001 Clinical Trial For ALS 6/30/2014 10:53:40 AM
Genervon Successfully Completes Its Phase 2a Clinical Trial For ALS 4/28/2014 11:14:58 AM
FDA Grants "Orphan Drug" Designation For Genervon’s Breakthrough Multi-Target ALS Bio-Drug GM604 3/3/2014 8:41:41 AM
FDA Granted Fast Track Designation for Genervon's Breakthrough Biotechnology Multi-Target ALS Drug GM604 Expediting Drug Approval Process 6/27/2013 10:40:15 AM